PP01.123: A Global Phase 3, Double-Blind, Randomized Trial of Pumitamig (BNT327/BMS986545; PD-L1 × VEGF-A bsAb) Plus Chemotherapy Compared to Atezolizumab Plus Chemotherapy in Patients with First-Line (1L) Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - ROSETTA Lung-01

PP01.123: A Global Phase 3, Double-Blind, Randomized Trial of Pumitamig (BNT327/BMS986545; PD-L1 × VEGF-A bsAb) Plus Chemotherapy Compared to Atezolizumab Plus Chemotherapy in Patients with First-Line (1L) Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - ROSETTA Lung-01 | ReachRx